Biomedical Imaging: The Chemistry of Labels, Probes and Contrast Agents

Front Cover
Martin Braddock
Royal Society of Chemistry, 2011 - Medical - 533 pages
0 Reviews
The focus of this new book is for medicinal chemists on the chemical agents that have been used, or might be required in the future, and the methods of synthesis for inserting the reporter groups. Medicinal chemists need to know the critical issues involved in using such chemical agents with regard to the biological applications - for instance - what properties are needed chemically and why? The topics covered in the book are: PET, SPECT, contrast agents, radioimaging/radionuclide conjugates, receptor mapping, small animal imaging (eg. WBAR - whole body autoradiography); photoinduced labelling, as well as chapters on the physical techniques used including: NMR, mass spectrometry and Xray. A key reference for academics, postgraduates, researchers, industrialists and professionals working in or joining this field.
 

What people are saying - Write a review

We haven't found any reviews in the usual places.

Contents

2 2 Protonation constants of the DOTA derivative ligands at 251C
238
3 MRI Contrast Agents Based on Metallofullerenes
261
Gadofullerene Gd3NC80
271
4 Application of Magnetic Resonance Imaging MRI
285
Planning
298
Autoradiography in Pharmaceutical Discovery
309
3 Design and Use of Contrast Agents for Ultrasound Imaging
391
1 Imaging as a CNS Biomarker
411
Advances in Radiotracer
21
Acknowledgments
39
Recent Developments in PET and SPECT Radioligands
49
1M Me4NCl 11 59 9 24 4 43 3 48 bpH 197 213
79
0MKCl11 36 7 35 3 83 2 12 1 29 bpH
87
Translocator Protein 18kD TSPO
91
EOB DTPA 0 1 MKCl 10 95 8 62 4 23 2 80 2 06 pH 208
105
pNO2Bn PCTA 1 0MKCl11 29 6 70 3 96 2 08 1 82 bpH 131
113

2 Magnetic Resonance Imaging in Drug Development
441
References
459
3 MRI in Practical Drug Discovery
465
4 Peering Into the Future of MRI Contrast Agents
490
Contents
xiv
Chapter
4
Ligands Electrolyte logK1H logK2H logK3H logK4H logK5H Method
10
References
20
References
115
Design and Synthesis of Radiopharmaceuticals
144
10
152
DTPA BBbuA 0 1MKCl 9 77 6 72 4 08 pH
158
References
168
RSC Drug Discovery Series No 15
173
References
202
Copyright

Common terms and phrases

About the author (2011)

Martin Braddock is a Senior Principal Scientist at AstraZeneca with extensive experience in drug discovery from target identification to lead optimisation. Dr Braddock has over 26 years research and management experience (including 15 years in Pharmaceutical Drug Discovery (AstraZeneca and GlaxoSmithKline) and 11 years holding academic positions, including 4 years as a Royal Society University Research Fellow at Oxford University. His research experience includes metabolic diseases, vascular, respiratory and inflammatory/autoimmune disease, HIV and AIDS research, alzheimer's, soft and hard tissue repair and regeneration. Elected Fellow of the Society of Biology in recognition of contribution to biological sciences. Invited Fellow of the Royal Society of Medicne.

Bibliographic information